Maternal and Fetal Adrenocorticotropic Hormone (ACTH) and Leukemia Inhibitory Factor (LIF) and Gestational Age
Overview
In 2010, Simamura et al have demonstrated in a rat model that one of the pro-inflammatory cytokine belonging to the Interleukin-6 family cytokines, LIF, is required for the proliferation of neuronal progenitor cells in the cerebrum. They have shown that maternal LIF induces ACTH from the placenta, which in turn stimulates fetal nucleated red blood cells to secrete LIF, leading finally to neurogenesis in the fetus As demonstrated recently in a mouse model, maternal inflammation suppress the physiological maternal- fetal LIF-ACTH-LIF signal, result in reduction of ACTH production from placenta, which lead to a reduction in LIF concentration in fetal Cerebrospinal fluid (CSF) and impaired proliferation of the neural stem/ progenitor cells and poor development of the fetal brain. In the current study, the investigators will take fetal and maternal blood samples of fetuses undergoing termination of pregnancy (TOP) . Maternal samples will be acquired with the routine blood samples before performance of TOP , fetal blood samples will be acquired from the umbilical vessel after the termination has been completed , the blood samples will be analyzed for levels of LIF and ACTH and checked according to termination pregnancy week, Patients electronic files will be checked for relevant demographic and obstetric information.
Full Title of Study: “The Correlation Between Gestational Age and Maternal and Fetal Levels of LIF and ACTH”
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: November 30, 2017
Detailed Description
Study protocol: In the current study, the investigators will take fetal and maternal blood samples of fetuses undergoing termination of pregnancy (TOP) . Maternal samples will be acquired with the routine blood samples before performance of TOP , fetal blood samples will be acquired from the umbilical vessel after the termination has been completed , the blood samples will be analyzed for levels of LIF and ACTH and checked according to termination pregnancy week, Patients electronic files will be checked for relevant demographic and obstetric information.
Interventions
- Diagnostic Test: Blood test
- blood samples will be taken for maternal and fetal levels of ACTH and LIF
Clinical Trial Outcome Measures
Primary Measures
- Maternal LIF levels during pregnancy
- Time Frame: up to 6 months
- Differences in levels of LIF according to gestational age
- Maternal ACTH levels during pregnancy
- Time Frame: up to 6 months
- Differences in levels of ACTH according to gestational age
- Fetal LIF levels during pregnancy
- Time Frame: up to 6 months
- Differences in levels of LIF according to gestational age
- Fetal ACTH levels during pregnancy
- Time Frame: up to 6 months
- Differences in levels of ACTH according to gestational age
Participating in This Clinical Trial
Inclusion Criteria
- Pregnant women undergoing termination of pregnancy in various gestational weeks. – Pregnant women undergoing spontaneous abortion. Exclusion Criteria:
•Intrauterine fetal death.
Gender Eligibility: Female
pregnant women undergoing termination of pregnancy
Minimum Age: 18 Years
Maximum Age: 44 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Rambam Health Care Campus
- Provider of Information About this Clinical Study
- Principal Investigator: Yuval Ginsberg, MD, Principal Investigator – Rambam Health Care Campus
- Overall Official(s)
- Yuval Ginsberg, MD, Principal Investigator, Rambam Health Care Campus
- Overall Contact(s)
- Yuval Ginsberg, MD, 0523571199, y_ginsberg@rambam.health.gov.il
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.